Several questions about the role of the oxygen sensor prolyl-hydroxylase 2 (PHD2) in cancer have not been addressed. First, the role of PHD2 in metastasis has not been studied in a spontaneous tumor model. Here, we show that global PHD2 haplodeficiency reduced metastasis without affecting tumor growth. Second, it is unknown whether PHD2 regulates cancer by affecting cancer-associated fibroblasts (CAFs). We show that PHD2 haplodeficiency reduced metastasis via two mechanisms: (1) by decreasing CAF activation, matrix production, and contraction by CAFs, an effect that surprisingly relied on PHD2 deletion in cancer cells, but not in CAFs; and (2) by improving tumor vessel normalization. Third, the effect of concomitant PHD2 inhibition in malignant and stromal cells (mimicking PHD2 inhibitor treatment) is unknown. We show that global PHD2 haplodeficiency, induced not only before but also after tumor onset, impaired metastasis. These findings warrant investigation of PHD2's therapeutic potential.
In Brief
Most breast cancer patients die of metastasis, yet the mechanisms underlying this process remain incompletely understood. Kuchnio et al. show that global haplodeficiency of PHD2 reduces metastasis by reducing the activation of cancer-associated fibroblasts and promoting tumor vessel normalization.
INTRODUCTION
Breast cancer (BC) is the most frequent cancer in women. BC remains the second leading cause of cancer death in women, primarily due to metastasis (Siegel et al., 2015) . Understanding the mechanisms governing BC metastasis and identifying strategies to block this process are needed.
Prolyl-hydroxylase 2 (PHD2) is an oxygen sensor that regulates HIFa levels in normoxia by targeting HIFa via hydroxylation for proteasomal degradation (Kaelin and Ratcliffe, 2008; Semenza, 2014) . We focused on PHD2 because of its critical role in health and disease, and because hypoxia signaling influences metastasis (De Bock et al., 2011) . Despite the importance of PHD2, its role in tumor growth and metastasis remains incompletely elucidated. Selective PHD2 haplodeficiency in ECs reduces metastasis without affecting tumor growth by normalizing tumor vessels (Leite de Oliveira et al., 2012; Mazzone et al., 2009) , while deficiency of PHD2 in immune cells decreases tumor growth (Mamlouk et al., 2014) . However, others reported that PHD2 silencing in cancer cells increases or decreases tumor growth via different underlying mechanisms (Klotzsche-von Ameln et al., 2011; Bordoli et al., 2011; Chan et al., 2009; Su et al., 2012; Wottawa et al., 2013) .
Although the role of PHD2 in tumor progression has been studied in transplantable tumors, three medically important questions were not addressed. First, though metastasis kills >90% of cancer patients, the consequences of blocking PHD2, selectively in cancer or stromal cells, on metastasis have not been dissected in a spontaneous tumor model, which more closely mimics human cancer. Second, it is unknown whether PHD2 regulates the behavior of cancer-associated fibroblasts (CAFs), despite emerging evidence that they modify tumor progression and metastasis (Quail and Joyce, 2013) . Third, while PHD2 silencing in cancer cells stimulated tumor progression in certain studies (Bordoli et al., 2011; Chan et al., 2009) , it remains unknown if concomitant PHD2 inhibition in both cancer and stromal cells (mimicking treatment with a pharmacological blocker) promotes or impairs metastasis, when initiated before but certainly also after onset of tumor growth in a spontaneous tumor model. In this study, we used the spontaneous Polyoma virus middle T antigen (PyMT)-oncogene driven BC model to address these questions.
RESULTS

Global PHD2 Haplodeficiency Reduces Metastasis
Since PHD2 has gene-dosage-dependent effects and homozygous PHD2 loss is embryonically lethal (Takeda et al., 2006) , we intercrossed global PHD2 haplodeficient mice with mice expressing the PyMT oncoprotein under control of the mouse mammary tumor virus (MMTV) promoter (MMTV-PyMT), a model that spontaneously develops metastatic mammary gland tumors and recapitulates features of human ductal BC (Lin et al., 2003) . Figure 1F ). 
(legend continued on next page)
RT-PCR analysis of cancer-cell-specific markers (Pymt; cytokeratin 8 [Krt8]) in the blood revealed that fewer cancer cells circulated in PyMT +/À mice (Figures 1G and S1G) . This was not due to a difference in survival of cancer cells in the blood, as verified by an in vitro clonogenic assay (mimicking non-adherent conditions in the blood) ( Figure 1H ), suggesting reduced cancer cell intravasation. PHD2 haplodeficiency did not reduce metastasis by affecting cancer cell extravasation and colonization, as analyzed respectively by RT-PCR of genes involved in extravasation ( Figure S1H ) or Pymt in the lungs after intravenous injection of PyMT +/À or PyMT +/+ cancer cells in wild-type recipient mice ( Figure S1I ). Thus, global PHD2 haplodeficiency impairs metastasis without affecting primary tumor growth in a spontaneous tumor model.
Effects of PHD2 Haplodeficiency on Cancer Cells
Global PHD2 Haplodeficiency Does Not Affect Cancer-Cell-Intrinsic Invasive Properties To explore the mechanism underlying the decrease in intravasation and metastasis of PyMT +/À tumors, we analyzed if PHD2 haplodeficiency impaired the invasive properties of isolated cancer cells in normoxia, using as positive controls hypoxia or hepatocyte growth factor (HGF) treatment, well-known inducers of epithelial-to-mesenchymal transition (EMT) (De Bock et al., 2011; Foubert et al., 2010; Waldmeier et al., 2012) . Although hypoxia stimulates cancer cell invasion (De Bock et al., 2011) and PHD2 haplodeficiency increased HIF1a and HIF2a levels in cancer cells (Figures S2A and S2B) , cancer cells from PyMT +/+ and PyMT +/À mice had a typical epithelial cobblestone-like morphology, did not exhibit signs of EMT (Figures 2A and 2B) , and did not show differences in protein or mRNA levels of factors involved in EMT and invasion (Figures 2C, 2D, and S2C) . Similarly, the response of PyMT +/+ and PyMT +/À cancer cells to HGF was largely comparable, except for a less pronounced effect on Twist1 and Snail2 expression in PyMT +/À cancer cells ( Figure S2C ). Also, cancer cell migration and invasion were comparable ( Figures 2E-2L ). Since previous studies documented only minimal EMT in MMTV-PyMT tumors (Trimboli et al., 2008) S3B ). We thus focused on CAFs, which promote tumorigenesis and metastasis (Augsten, 2014; Calvo et al., 2013; Lu et al., 2012) . PyMT +/À tumors contained fewer PDFGRa + CAFs (Figures 3A-3C) . Notably, this genotypic difference in CAF activation became evident beyond 11 weeks, when tumors progress from adenoma to carcinoma (Calvo et al., 2013) and the genotypic difference in metastasis became evident. This temporal association between CAF activation and metastasis raised the question if both processes were linked.
To further investigate the properties of CAFs, we isolated stromal mesenchymal cells from PyMT tumors. Previous studies reported that, once normal fibroblasts are activated to CAFs, they maintain their features in vitro, in part because they sustain their activation via autocrine production of TGF-b1 and SDF-1a (Kojima et al., 2010) . Consistent herewith, transcripts of Tgfb1 and Sdf1a were higher in PyMT +/+ CAFs than PyMT +/À CAFs in vitro ( Figure S3C (Calvo et al., 2013) . We embedded CAF spheroids in a collagen I gel and monitored sprout formation. Compared to cancer cells, CAFs formed more and longer sprouts (Figures 3F and 3G;  (E and L) The indicated significance relates to the respective control (Ctrl) condition; p = non-significant between genotype for the same experimental condition (Ctrl, HGF or hypoxia). 3I ). In agreement, the levels of matrix metalloproteinases (Mmp2, Mmp9), implicated in proteolytic matrix degradation during CAF invasion (Lu et al., 2012) , were reduced in PyMT +/À CAFs ( Figure 3J ). Thus, PyMT +/À CAFs displayed invasion defects.
Impaired Matrix Deposition and Cross-linking by Global PyMT +/À CAFs
CAFs facilitate cancer cell invasion via various effects on the matrix, for instance, by depositing bundles of cross-linked collagen I, which cancer cells use as migration tracks (Calvo et al., 2013; Lu et al., 2012) . We verified that CAFs were a source of matrix production in PyMT tumors. Analysis of [ (F-I) CAF spheroid invasion assay using PyMT +/+ (F) and PyMT +/À (G) CAFs. (H and I) Quantification of invasive sprout length (H) and number (I) (n > 14 spheroids).
(J) RT-PCR for Mmp2 and Mmp9 in PyMT +/+ and PyMT +/À CAFs (n = 3).
Scale bar, 50 mm (A and B) or 100 mm (F and G). All quantitative data are mean ± SEM. *p < 0.05, ** p < 0.01, *** p < 0.001. See also Figure S3 .
incorporation in the deposited matrix revealed that CAFs produced larger amounts of matrix than PyMT cancer cells ( Figure S4A ). Figure 4G ). Fourth, the reduced matrix production was not only a result of the decreased proliferation of PyMT +/À CAFs, as PyMT +/À CAFs also had lower mRNA levels of genes encoding collagen lysyl oxidase (Lox), prolyl hydroxylases (P4ha1, P4ha2), and lysyl (Plod2) CAFs also facilitate cancer cell invasion by remodeling the matrix via active contraction (Calvo et al., 2013) , a process resulting in matrix stiffening that promotes cancer cell invasion and metastasis (Calvo et al., 2013; Lu et al., 2012) . Given that CAFs require a contractile cytoskeleton for matrix contraction (Calvo et al., 2013) and PyMT +/À CAFs had decreased amounts of immunoreactive aSMA + stress fibers ( Figures S3D-S3F ), we studied if the ability of PyMT +/À CAFs to contract the matrix was impaired. We used the ''collagen contraction assay,'' in which CAFs are uniformly dispersed in a collagen I gel (Calvo et al., 2013) . By contracting the gel, CAFs reduce the size of the gel. This analysis revealed that PyMT +/À CAFs contracted the collagen gel less than PyMT +/+ CAFs ( Figure 4H ).
To assess whether remodeling of the collagen gel by the CAFs' contractile activity altered the invasion of PyMT +/+ cancer cells, we embedded cancer cell spheroids in a collagen gel containing uniformly dispersed CAFs ( Figure S4G (Orimo et al., 2005) , co-transplantation of CAFs increased tumor growth irrespective of the CAF genotype ( Figure 4M ). Also, metastatic dissemination 6 weeks after transplantation was increased upon co-transplantation of PyMT +/+ cancer cells and PyMT +/+ CAFs ( Figures 4N and 4O ). Interestingly however, fewer metastases formed when cancer cells were co-implanted with PyMT +/À CAFs ( Figures 4N and 4O (Quail and Joyce, 2013) . Given that silencing of PHD2 in BC cells reduced TGF-b1 secretion (Wottawa et al., 2013), we investigated if reduced activation of CAFs was due to a reduction in TGF-b1 secretion by PyMT +/À cancer cells. ELISA showed that TGF-b1 levels were reduced in the supernatant of PyMT +/À cancer cells ( Figure 5A ). Interestingly, this was not paralleled by a reduction in Tgfb1 mRNA levels ( Figure S5L) Figures 6A-6C ). Furthermore, induction of the CAF phenotype was prevented when TGF-b1 was immuno-neutralized ( Figures 6A-6C ), suggesting that TGF-b1 is a key regulator of CAF activation in the MMTV-PyMT tumor model.
Global and Endothelial PHD2 Haplodeficiency Induces Tumor Vessel Normalization
Although metastasis in PyMT TC-HE mice was reduced, the reduction was smaller than in PyMT +/À mice, suggesting that another mechanism might also contribute to the phenotype. We therefore considered an effect on tumor vessels, given that endothelial PHD2 haplodeficiency normalizes tumor vessels and thereby impairs metastasis (Leite de Oliveira et al., 2012; Mazzone et al., 2009) . Confirming findings from transplanted tumors, global PHD2 haplodeficiency induced tumor vessel normalization, characterized by reduced hypoxia (Figures 7A-7C ), increased vessel perfusion and maturation without changing vessel density ( Figures 7D-7N and S6A-S6I), and improved endothelial cell lining ( Figures 7O and 7P ). These findings were recapitulated in two models of endothelial-selective PHD2 haplodeficiency, obtained by crossing PHD2 mice at 7 weeks (3 weeks after tumor onset) did not affect tumor growth but reduced pulmonary metastasis ( Figures  7Q-7S ). Immunoblotting revealed that PHD2 levels in tumor extracts of PyMT R26-HE mice were reduced by $50%
( Figure S7A ). To study whether pharmacological inhibition of PHD2 copied key phenotypes of PHD2 haplodeficiency (more in particular, whether it impaired CAF activation by reducing TGF-b1 secretion by cancer cells), we used IOX2, a pharmacological prolyl-hydroxylase inhibitor with higher specificity for PHD2 (Chowdhury et al., 2013) . Treatment of PyMT cancer cells with 50 mM IOX2 for 48 hr, a concentration that upregulated HIF1a and HIF2a levels ( Figure S7B ), decreased TGF-b1 secretion ( Figure 7T ). Importantly, treatment of normal fibroblasts with the conditioned medium of IOX2-treated PyMT cancer cells impaired activation of CAFs ( Figure S7C) .
Finally, to explore clinical relevance, we assessed if EGLN1 (PHD2) mRNA levels correlated with the expression of genes involved in CAF activation in human BC samples by mining the METABRIC (Curtis et al., 2012) and The Cancer Genome Atlas (TCGA) databases. We analyzed 691 human breast tumors (of which $75% were ductal carcinomas) from the TCGA database and 1,548 human ductal breast tumors from the METABRIC database. We stratified these tumors for high and low expression of EGLN1, defining ''low'' when EGLN1 levels were <60% of the average EGLN1 expression in the study population. This analysis revealed that expression of ACTA2, PDGFRA, and SDF1A were downregulated in the low-EGLN1 patient group ( Figures 7U and  S7D ), similar to our findings in PyMT +/À tumors. The expression of S100A4 (FSP1) was also lower, but it only reached significance in ductal BCs ( Figure 7U ). The expression of TGFB1 was higher in the low-EGLN1 group, but this might be due to the contribution of TGFB1 expression by cancer cells. Indeed, Tgfb1 mRNA levels were similar in PyMT +/+ and PyMT +/À cancer cells ( Figure S5L ).
DISCUSSION
Treatment of BC metastasis remains an unmet medical need. This study identifies PHD2 as a promising target to reduce metastasis in BC. Using a spontaneous BC model, we show that haplodeficiency of PHD2 in both cancer and stromal cells does not affect tumor growth but impairs metastasis via two mechanisms: (1) reduced CAF activation as a result of altered paracrine crosstalk from cancer cells to stromal CAFs and (legend continued on next page) (2) tumor vessel normalization. In turn, primed CAFs reciprocally affect cancer cells by modulating their invasive behavior via pleiotropic effects on the matrix. The model is represented in Figure S7E .
PHD2-Dependent Regulation of Cancer Cell Invasion by CAFs
BC cells invade tissues in different ways. If they undergo EMT, then they acquire invasive properties and breach matrix-dense tissue barriers (Friedl and Wolf, 2003) . If not, they invade tissues via collective migration, especially when assisted by invasive CAFs (Calvo et al., 2013; Friedl and Wolf, 2003) . In line with previous reports (Trimboli et al., 2008) , we observed only minimal signs of EMT in this BC model. Wild-type cancer cells alone (without co-invading CAFs) invaded the collagen gel only minimally. PHD2 did not control these cancer-cell-intrinsic invasive processes. In contrast, CAFs stimulated the invasion of cancer cells when they were co-cultured with cancer cells, a process that was under the control of PHD2 in cancer cells. CAFs modulate cancer cell invasion via several complementary mechanisms. First, these cells alter cancer cell invasion by depositing bundles of cross-linked collagen, known migration ''highways'' for invading cancer cells (Lu et al., 2012) . Our findings not only indicate that CAFs were a prominent source of matrix production in PyMT tumors but also reveal that CAFs from PyMT +/À and PyMT TC-HE mice deposited smaller amounts of thick bundles of cross-linked collagen. A second mechanism relies on the remodeling of the tumor matrix by proteolysis. By proteolytically remodeling the ECM, CAFs can (1) physically free up space for invading cancer cells, (2) liberate matrix-bound migratory signals, or (3) alter biochemical/structural properties of matrix components, all stimulating cancer cell migration (Lu et al., 2012) . In line, CAFs, primed by PHD2 haplodeficient cancer cells, produced less matrix-degrading metalloproteinases.
A third mechanism whereby CAFs regulate cancer cell invasion is by remodeling the matrix via contraction (Calvo et al., 2013) . The latter process induces alignment of collagen fibers, which enhances cross-linking of collagen fibers and increases matrix stiffness (Calvo et al., 2013) . The importance hereof is highlighted by the fact that matrix stiffness promotes cancer cell invasion and dissemination (Provenzano et al., 2006) . Noteworthy, since remodeling of the matrix by CAFs enhances the activation of the CAFs themselves, a self-sustaining feed-forward loop of CAF activation and matrix remodeling is initiated that progressively aggravates malignancy (Lu et al., 2012) . Our findings indicate not only that PyMT +/À and PyMT TC-HE tumors contained fewer activated CAFs but also that CAFs, primed by PHD2 haplodeficient cancer cells, expressed lower levels of the contractile protein aSMA and contracted the collagen gel less. Also, the amount of cross-linked collagen fibers was reduced in PyMT +/À tumors. Together, these mechanisms explain why CAFs, primed by PHD2 haplodeficient cancer cells, did not enhance the invasive behavior of cancer cells to the same extent as CAFs, primed by PyMT TC-WT cancer cells. Since such invasive activity assists cancer cells to travel through the tumor matrix and breach the endothelial barrier during intravasation (van Zijl et al., 2011) , these mechanisms can explain why metastasis was lower in PyMT TC-HE than PyMT TC-WT tumors ( Figure S7E ). In this sense, cancer cells ''highjack'' their neighbors, the CAFs, to facilitate (M and N) CAF spheroid invasion assay using PyMT TC-WT (M) and PyMT TC-HE (N) CAFs. O, Collagen gel contraction assay using PyMT TC-WT or PyMT TC-HE CAFs (n = 6; t test with Welch's correction). Inset: representative pictures of contracted gel.
(P-R) Invasion assay using spheroids of Tomato + PyMT mT/mG cancer cells (CCs, red) in collagen gels into which GFP + CAFs (green) isolated from PyMT TC-WT (P) or from PyMT TC-HE (Q) tumors were homogeneously dispersed. PyMT +/+ mice were intercrossed with mT/mG reporter mice (Muzumdar et al., 2007) to obtain Tomato + PyMT mT/mG CCs; CAFs were transduced with a GFP-expressing lentiviral vector (see Supplemental Experimental Procedures). (R) Quantification of the area of the entire CCs spheroids (n > 18 spheroids). Scale bar, 50 mm (D, E, I, and J) or 100 mm (M, N, P, and Q). All quantitative data are mean ± SEM *p < 0.05, ** p < 0.01, *** p < 0.001. See also Figure S5 . (legend continued on next page) their own escape. Another implication is also that even in the absence of prominent alterations in intrinsic invasive behavior of cancer cells (migration, EMT), a change in CAF behavior suffices to alter metastasis.
PHD2-Dependent Regulation of TGF-b1 Crosstalk
Silencing of PHD2 in BC cells reduces TGF-b1 secretion (Wottawa et al., 2013) . In agreement, PHD2 haplodeficient PyMT cancer cells released less TGF-b1. Given that TGF-b1 induces differentiation of normal fibroblasts to CAFs (Calon et al., 2014; Evans et al., 2003) , the lower levels of TGF-b1 secreted by PyMT +/À cancer cells could thus explain the reduced activation of CAFs from PyMT +/À mice. Also, mRNA levels of Sdf1a and Tgfb1 were lower in CAFs from PyMT +/À mice. These cytokines are released by activated CAFs as autocrine signals to maintain an activated state (Kojima et al., 2010) . Together, the data suggest a model whereby PHD2 haplodeficient cancer cells reduce the activation of CAFs by releasing less TGF-b1. These hypoactivated CAFs in turn maintain their reduced activation by expressing lower levels of the autocrine activation signals Sdf1a and Tgfb1, resulting in a self-suppressing loop. TGF-b1 has contextual effects. On one hand, this cytokine stimulates cancer progression via effects on myofibroblasts (CAFs) that indirectly stimulate cancer cell motility and proliferation (Calon et al., 2014; Siegel and Massagué , 2003) , but on the other hand, loss of the TGF-bR2 receptor in fibroblasts promotes cancer progression and metastasis (Cheng et al., 2005; Fang et al., 2011) . Regardless of these contextual activities, the neutralization studies showed that TGF-b1 activated-not suppressed-CAFs in the PyMT model used.
An outstanding question is whether this phenotype relies on HIF signaling. As expected, HIF1a and HIF2a levels were elevated in PyMT +/À cancer cells ( Figures S2A and S2B ). However, deep silencing of HIF1a or HIF2a was toxic for PyMT cancer cells. Incomplete silencing of HIFs or treatment with a low concentration of the HIF dimerization blocker acriflavine (5 mM), which partially inhibited the HIF-transcriptional activity in PyMT cancer cells, did not restore TGF-b1 release by PyMT +/À cancer cells to levels observed in PyMT +/+ cancer cells (not shown). In fact, acriflavine treatment even further decreased TGF-b1 release by PyMT +/À cancer cells (not shown). Altogether, these results suggest that the reduction in TGF-b1 secretion by PyMT +/À cancer cells was likely independent of HIF. This may also explain why our phenotype is not opposite to the one of mice lacking HIF1a in the mammary epithelium in the same PyMT model (Liao et al., 2007) .
PHD2 Haplodeficiency Induces Tumor Vessel Normalization
Global or endothelial haplodeficiency of PHD2 reduced metastasis as well. Because tumor vessels are structurally and functionally abnormal, tumor perfusion is reduced and cancer cells become more deprived of oxygen and nutrients and thus attempt to escape from this hostile microenvironment via metastasis. In addition, cancer cells use the gaps in the leaky endothelium as gateways to intravasate (Carmeliet and Jain, 2011) . By normalizing these processes; i.e., by improving tumor oxygenation and tightening the endothelial layer, PHD2 haplodeficiency counteracts cancer cell invasion and metastasis. These findings in a spontaneous tumor model are consistent with previous findings in transplanted tumor models (Leite de Oliveira et al., 2012; Mazzone et al., 2009 ).
Role of PHD2 in Cancer
Other studies characterized the role of oxygen sensors in tumor biology, but the large majority of them focused on their role in cancer cells, not in stromal cells. Also, these studies reported divergent (even opposite) effects of silencing PHD2 in malignant cells (Klotzsche-von Ameln et al., 2011; Bordoli et al., 2011; Chan et al., 2009; Su et al., 2012; Wottawa et al., 2013) . However, only two studies evaluated the role of cancer cell PHD2 in metastasis, but they did not assess the role of PHD2 in stromal cells (Klotzsche-von Ameln et al., 2011; Naba et al., 2014) . In contrast, by concomitantly blocking PHD2 in cancer and stromal cells, we provide mechanistic insight in how cancer cell PHD2 regulates CAF behavior and thereby invasion and metastasis, and we document a benefit of PHD2 blockade on metastasis.
Possible Translational Implications A retrospective analysis in two different databases revealed that lower EGLN1 (PHD2) levels in human BC samples correlated with reduced expression of CAF markers, extending our preclinical observations. From a therapeutic perspective, blocking PHD2's CAF-dependent pro-metastatic activity might offer opportunities to suppress metastasis. Our genetic evidence illustrates that global PHD2 haplodeficiency, even when initiated after tumor onset, still decreased metastasis. This implies that administration of a pharmacological PHD2 blocker, inhibiting PHD2 in both cancer and stromal cells, might offer therapeutic benefit in preventing or minimizing metastatic disease. Finally, tumor promotion is an often-stated potential side effect of hydroxylase inhibitors; however, the current data argue against such concern, at least in the PyMT model. Obviously, additional spontaneous tumor models should be explored before such statement can be generalized.
EXPERIMENTAL PROCEDURES
More detailed methods are described in the Supplemental Experimental Procedures.
Mice
Transgenic female FVB/n mice expressing the polyoma middle T antigen oncogene under the mouse mammary tumor virus promoter (MMTVPyMT) were used, with or without global or epithelial-, fibroblast-, or endothelial-specific haplodeficiency of PHD2 (see the Supplemental Experimental Procedures). Animal procedures were approved by the institutional animal care and research advisory committee (KU Leuven) and performed in accordance with the institutional and national guidelines and regulations.
Cell Culture and In Vitro Functional Assays MMTV-PyMT cancer cells and CAFs were isolated according to modified protocols (Calvo et al., 2013; Schwab et al., 2012) . Proliferation was quantified by measuring [ 3 H]-thymidine incorporation. Clonogenic growth (the number of colonies formed by single cells cultured on agar) was analyzed after 10 days. For the spheroid invasion assay, MMTV-PyMT cancer cell or CAF spheroids were embedded in a collagen gel and cultured for 72 or 18 hr, respectively, to allow invasion. NIH ImageJ software was used to analyze invasion. Migration was analyzed using the scratch wound-healing assay. ECM synthesis and remodeling were assessed on in vitro cellderived matrices ([ 3 H]-L-proline incorporation) and a collagen contraction assay, respectively, as detailed in the Supplemental Experimental Procedures.
RT-PCR, Immunoblotting, and Immunocytochemistry RNA expression analysis was performed by TaqMan qRT-PCR. Immunoblotting and immunostaining of proteins was performed using the antibodies listed in the Supplemental Experimental Procedures.
Tumor Model
The volumes of each of the ten mammary tumors per MMTV-PyMT mouse were measured once a week up to 16 weeks with a caliper using the formula V = p 3 [d 2 3 D] / 6, where D is the major tumor axis and d is the minor tumor axis. Per mouse the average of the individual tumor volumes was calculated. Tumor weight and pulmonary metastasis was analyzed upon dissection of tumors and lungs from euthanized mice.
Human BC Database Analysis
Human BC databases were downloaded from the TCGA server or through Synapse (https://www.synapse.org) and were analyzed as further detailed in the Supplemental Experimental Procedures. The use of data from the META-BRIC database has been approved by the Institutional Medical Ethical Committee (UZ Leuven 58011).
Statistics
Data represent mean ± SEM. Unless otherwise indicated, statistical significance was calculated by standard two-sided t test with F-testing to confirm equality of variance (Prism v6.0b). In case of unequal variance, two-sided t test with Welch's correction was used (Prism v6.0b). p < 0.05 was considered statistically significant.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures and seven figures and can be found with this article online at http://dx.doi. org/10.1016/j.celrep.2015.07.010.
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